Prediction and management of cardiovascular outcomes in systemic lupus erythematosus

被引:10
作者
Frostegard, Johan [1 ]
机构
[1] Karolinska Inst, Unit Immunol & chron Dis, IMM, S-17175 Stockholm, Sweden
关键词
antibodies; atherosclerosis; cardiovascular disease; inflammation; risk factors; systemic lupus erythematosus; CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; VULNERABLE CAROTID PLAQUES; RISK-FACTORS; ATHEROSCLEROTIC PLAQUES; RHEUMATOID-ARTHRITIS; DENDRITIC CELLS; ACCELERATED ATHEROSCLEROSIS; AGGRAVATES ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION;
D O I
10.1586/1744666X.2015.993970
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Atherosclerosis is the major cause of cardiovascular disease (CVD), which represents the major cause of death. During recent years, it has become clear that atherosclerosis is a chronic inflammatory condition where immunity could play an important role. Usually, it is when atherosclerotic plaques rupture that CVD follows, but some cases of CVD can occur without apparent atherosclerosis. In systemic lupus erythematosus, the risk of CVD is very high and the prevalence of atherosclerotic plaques, including vulnerable ones, is increased. A combination of traditional and non-traditional risk factors is implicated for the prediction of CVD in systemic lupus erythematosus. Traditional risk factors include hypertension, dyslipidemia, smoking and diabetes, though the exact importance of each of these in systemic lupus erythematosus is not clear. Anti-phospholipid antibodies, systemic inflammation and low levels of natural antibodies such as those against phosphorylcholine (anti-PC) are examples of non-traditional risk factors. Control of disease activity and disease manifestations and of established risk factors is important.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 76 条
  • [1] Myocardial infarction with angiographically normal coronary arteries
    Agewall, S.
    Eurenius, L.
    Hofman-Bang, C.
    Malmqvist, K.
    Frick, M.
    Jernberg, T.
    Tornvall, P.
    [J]. ATHEROSCLEROSIS, 2011, 219 (01) : 10 - 14
  • [2] Natural regulatory T cells control the development of atherosclerosis in mice
    Ait-Oufella, H
    Salomon, BL
    Potteaux, S
    Robertson, AKL
    Gourdy, P
    Zoll, J
    Merval, R
    Esposito, B
    Cohen, JL
    Fisson, S
    Flavell, RA
    Hansson, GK
    Klatzmann, D
    Tedgui, A
    Mallat, Z
    [J]. NATURE MEDICINE, 2006, 12 (02) : 178 - 180
  • [3] Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus
    Anania, Cristina
    Gustafsson, Thomas
    Hua, Xiang
    Su, Jun
    Vikstrom, Max
    de Faire, Ulf
    Heimburger, Mikael
    Jogestrand, Tomas
    Frostegard, Johan
    [J]. ARTHRITIS RESEARCH & THERAPY, 2010, 12 (06)
  • [4] Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein
    Ardoin, Stacy P.
    Schanberg, Laura Eve
    Sandborg, Christy I.
    Barnhart, Huiman X.
    Evans, Greg W.
    Yow, Eric
    Mieszkalski, Kelly L.
    Ilowite, Norman T.
    Eberhard, Anne
    Imundo, Lisa F.
    Kimura, Yuki
    Levy, Deborah
    von Scheven, Emily
    Silverman, Earl
    Bowyer, Suzanne L.
    Punaro, L.
    Singer, Nora G.
    Sherry, David D.
    McCurdy, Deborah K.
    Klein-Gitelman, Marissa
    Wallace, Carol
    Silver, Richard M.
    Wagner-Weiner, Linda
    Higgins, Gloria C.
    Brunner, Hermine I.
    Jung, Lawrence
    Soep, Jennifer B.
    Reed, Ann M.
    Thompson, Susan D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (03) : 557 - 566
  • [5] Bobryshev YV, 1997, J SUBMICR CYTOL PATH, V29, P209
  • [6] Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies
    Borba, EF
    Bonfa, E
    [J]. LUPUS, 1997, 6 (06) : 533 - 539
  • [7] Treatment With Methotrexate Inhibits Atherogenesis in Cholesterol-Fed Rabbits
    Bulgarelli, Adriana
    Martins Dias, Adriana Abalen
    Caramelli, Bruno
    Maranhao, Raul Cavalcante
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2012, 59 (04) : 308 - 314
  • [8] HEART IN SYSTEMIC LUPUS-ERYTHEMATOSUS AND CHANGES INDUCED IN IT BY CORTICOSTEROID-THERAPY - STUDY OF 36 NECROPSY PATIENTS
    BULKLEY, BH
    ROBERTS, WC
    [J]. AMERICAN JOURNAL OF MEDICINE, 1975, 58 (02) : 243 - 264
  • [9] IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes
    Caidahl, Kenneth
    Hartford, Marianne
    Karlsson, Thomas
    Herlitz, Johan
    Pettersson, Knut
    de Faire, Ulf
    Frostegard, Johan
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (02) : 464 - 469
  • [10] Decreased binding of annexin V to endothelial cells -: A potential mechanism in atherothrombosis of patients with systemic lupus erythematosus
    Cederholm, A
    Svenungsson, E
    Jensen-Urstad, K
    Trollmo, C
    Ulfgren, AK
    Swedenborg, J
    Fei, GZ
    Frostegård, J
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (01) : 198 - 203